Antibiotic Resistance and Pathogenicity of Bacterial Infections Research Group
Research group of the Health Research Institute of the Balearic Islands (IdiSBa, Group information). Founded in 2002 and accredited as a competitive research group by the Autonomous Community of the Balearic Islands, the group is composed of basic and clinical researchers from the Son Espases University Hospital (HUSE, Service information) from various specialties, with extensive experience and a long-standing collaborative trajectory in the field of infectious disease research.
The group is part of the Consorcio Centro de Investigación Biomédica en Red (CIBER) in Infectious Diseases (CIBERINFEC) of the Carlos III Health Institute (ISCIII).
Latest news
A multirange paper-based analytical device for identifying low, moderate, and high P. aeruginosa bacterial loads in sputum samples.
Adrover-Jaume C; Clemente A; Viana-Ramírez J; Rojo-Molinero E; Oliver A; de la Rica R Abstract: In this article we introduce a multirange analytical device that extends the dynamic range of nanoparticle-based immunoassays thanks to a multisensor design. Multirange devices contain low- and high-range sensors in the same analytical platform. The low-range sensor defines the limit of detection and quantifies low...
In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide.
Roson-Calero N; Gomis Font MA; Ruiz-Soriano A; Just-Baringo X; Pachón-Ibáñez ME; Salvador JP; Marco MP; Giralt E; Oliver A; Ballesté-Delpierre C; Vila J Abstract: The pipeline for new drugs against multidrug-resistant Pseudomonas aeruginosa remains limited, highlighting the urgent need for innovative treatments. New strategies, such as membrane-targeting molecules acting as adjuvants, aim to enhance antibiotic effectiveness and combat resistance. RW01,...
Impact of Pseudomonas aeruginosa carriage on intensive care unit-acquired pneumonia: a European multicentre prospective cohort study.
Recanatini C; van Werkhoven CH; van der Schalk TE; Paling F; Hazard D; Timbermont L; Torrens G; DiGiandomenico A; Esser MT; Wolkewitz M; Sifakis F; Goossens H; Bonten M; Oliver A; Malhotra-Kumar S; Kluytmans J Abstract: Pseudomonas aeruginosa (PA) is a common causative pathogen of pneumonia acquired in the intensive care unit (ICU). The aim of this study was to...
Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?
Pina-Sánchez M; Rua M; López-Causapé C; Bilbao I; Sastre-Femenia MÀ; Oliver A; Del Pozo JL Abstract: Few active antibiotic options are available to treat MBL-producing Pseudomonas aeruginosa infections, and some of these options are either poorly tolerated or have pharmacokinetic limitations. The use of aztreonam monotherapy for treating MBL-producing P. aeruginosa remains controversial due to the risk of selecting resistant...
Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa.
Sastre-Femenia MÀ; Gomis-Font MA; Oliver A Abstract: A growing number of novel antipseudomonal β-lactams have been introduced in recent years, but the emergence of resistance is still a major concern in the treatment of Pseudomonas aeruginosa infections. Here, we compared the mutant prevention concentrations (MPCs) and the nature of first-step resistant mutants to classical and novel β-lactams in P. aeruginosa....
How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today’s clinicians.
Horcajada JP; Gales A; Isler B; Kaye KS; Kwa AL; Landersdorfer CB; Montero MM; Oliver A; Pogue JM; Shields RK; Villegas MV; Yahav D; Paterson DL Abstract: Pseudomonas aeruginosa has a remarkable ability to develop resistance to antimicrobials in vivo, often leaving very limited therapeutic options and making treatment particularly challenging. In fact, P. aeruginosa infections with “difficult-to-treat resistance” are...